Ascletis ASC36_35FDC shows dosing potential, weight-loss in preclinical studies

Ascletis announced that its ASC36_35FDC drug candidate demonstrated potential for once-monthly to once-quarterly dosing and robust weight-loss in preclinical studies. The results were presented at the European Association for the Study of Diabetes (EASD) 2026.